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Abstract:  
Eight derivatives of 4-aminoquinolines differing inthe substituents attached to the C(4)-
amino group and C(7) were synthesised and tested as inhibitors of human acetylcholinesterase 
(AChE) and butyrylcholinesterase (BChE). Both enzymes were inhibited by all of the 
compounds with inhibition constants (Ki) ranging from 0.50 to 50 µM exhibiting slight 
selectivity toward AChE over BChE. The most potent inhibitors of AChE were compounds 
with an n-octylamino chain or adamantyl group. The shortening of the chain length resulted in 
a decrease in AChE inhibition by 5-20 times. Docking studies revealed that the quinoline 
group within the AChE active site was positioned in the choline binding site, while the C(4)-
amino group substituents, depending on their lipophilicity, could establish hydrogen bonds or 
π-interactions with residues of the peripheral anionic site. The most potent inhibitors of BChE 
were compounds with the most voluminous substituent on C(4)-amino group (adamantyl) or 
those with a stronger electron withdrawing the substituent on C(7) (trifluormethyl group). 
Based on AChE inhibition, compounds with an n-octylamino chain or adamantyl substituent 
were shown to possess the capacity for further development as potential drugs for treatment of 
neurodegenerative diseases. 
 

















Derivatives of 4-aminoquinoline are one of the most used and most useful antimalarial 
agents in treating erythrocytic plasmodial infections from which chloroquine, 
hydroxychloroquine and amodiaquine are considered th  most important drugs for the control 
and extermination of malaria. Apart from an original indication to prevent or cure malaria, 
these compounds also have anti-inflammatory, immunoodulating, anti-infective and 
antithrombotic activity, and have displayed metabolic effects and antitumoral properties [1]. 
Many studies have demonstrated that compounds based on a quinoline structure are potent 
inhibitors of both cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase 
(BChE) [2, 3]. As their primary structural motive, these compounds have tacrine or quinidine 
moiety [4-9]. Furthermore, anticholinesterase activity has been confirmed for antimalarial 
drugs chloroquine, hydroxychloroquine and primaquine [10-12]. These compounds are 
derivatives of 4-aminoquinolines which were recently pointed out as a promising starting 
structural scaffold for the further design of novel multifunctional AChE inhibitors considering 
the simple structure and high inhibitory potency against AChE [13]. 
BChE and AChE are related enzymes that share more than 54% of their amino acid 
sequence and an active site located in a 20 Å deep gorge [14-16]. The active site of both 
AChE and BChE is divided into two sub-sites; the catalytic site (CAS) located close to the 
bottom of the gorge and the peripheral anionic site (PAS) located at the entrance of the gorge. 
CAS is composed of the catalytic triad, an oxyanion hole, an acyl-binding pocket and a 
choline binding site [17-19]. The active site of BChE differs in six out of the 14 aromatic 
residues lining AChE, which have aliphatic residues on corresponding places in BChE [16, 
18, 19]. These differences lead to different interactions with the same substrates and ligands 
and defined AChE and BChE specificity and selectivity [20-24]. 
 We synthesised eight derivatives of 4-aminoquinolines differing in the substituent 
attached to the C(4)-amino group and C(7) (Figure 1). The aim of this study was to test their 
inhibition potency toward human AChE and BChE, evaluate their inhibition selectivity and 
interpret obtained kinetic results by molecular modelling. Moreover, we evaluated the 
physicochemical properties of the tested compounds to e timate their capacity to penetrate the 


















Fig. 1. Chemical structure of the tested compounds. 
 
2. Materials and methods 
 
2.1. Chemicals  
All of the chemicals, reagents and solvents for thepr paration of 4-aminoquinoline 
derivatives were purchased from commercial sources. Acetylthiocholine (ATCh) and 5,5´-
dithiobis(2-nitrobenzoic acid) (D NB) were purchased from Sigma Chemical Co., USA. 
ATCh was dissolved in water and DTNB in 0.1 M sodium phosphate buffer (pH 7.4). 4-
aminoquinilines were dissolved in DMSO and all further dilutions were made in water.  
 
2.2. Enzymes 
Purified human BChE and recombinant human AChE were kindly provided by Dr Florian 
Nachon (Département de Toxicologie, Armed Forces Biomedical Research Institute, France). 
The concentration of the stock solution of enzymes (BChE: 5.6 µM; AChE: 0.20 µM) was 
determined as described previously [25]. The enzymes w re diluted in a phosphate sodium 

















The investigated compounds were synthetized as previously described [26, 27]. Briefly, the 
starting 4-chloroquinolines 1 or 2 were heated at 130 oC in the presence of a corresponding 
amine (Scheme 1, route a), or (NH4)2CO3 in phenole (Scheme1, route b), for defined reaction 
time. The reaction mixture was cooled at room temperature, water was added and crude 
product was filtered, rinsed with water, dried and prepare for purification by column 
chromatography (dry flash). For compound CQ reaction mixture in phenol was cooled to 
room temperature, ethyl-acetate was added and solution was washed with 0.1 M NaOH until 
excess of phenol was removed, twice with brine and dried over Na2SO4 anh. The solution was 
filtered, solvent was removed under reduced pressur and crude product was purified by 
column chromatography (dry flash). CQAd was obtained via reductive amination starting 
from adamantane-1-carbaldehyde and N-(7-chloroquinolin-4-yl)propane-1,3-diamine 
(compound 3, Scheme 1). After the complete consumption of the starting 3, the solvent was 
removed under reduced pressure and the final product was obtained after column 
chromatography (dry flash). Chloroquine was obtained after neutralisation of commercial 
drug chloroquine-diphosphate with 0.1 M NaOH. Obtained grounds were filtered of, rinsed 
with water and dried. The identity and purity of the obtained compounds were verified with 




















2.4. Inhibition measurements 
 Enzyme activity was measured spectrophotometrically by the Ellman method using 
acetylthiocholine (ATCh; 0.050-0.50 mM) as substrate in 0.1 M phosphate buffer, pH 7.4 [28, 
29]. The decrease of AChE and BChE activity towards ATCh was measured in the presence 
of aminoquinolines (final concentrations 0.25 - 200 µM, depending on the compound). The 
final content of DMSO in measurements was up to 0.2%. No side interactions of the tested 
compounds with ATCh or DTNB were detected. Measurements were done at 25 °C on a 
Tecan Infinite M200Pro plate reader (Austria). 
 The activities of the enzymes were measured at different substrate concentrations (s) 
in the absence (v0) and presence (vi) of a given aminoquinolines concentration (i) selected to 
inhibit the enzymes for 20 - 80%. At least three concentrations of inhibitors for each substrate 
concentration were used in at least two experiments. The apparent inhibition constant (Ki,app) 
was calculated using the Hunter-Downs equation and the linear regression analysis [30]: 
Ki,app = vi·i / (v0-vi) = Ki + Ki / K(s)·s        (1) 
where y-intercept determines the enzyme-inhibitor dissociation constants (Ki), while x-
intercept determines the enzyme-substrate dissociati n constant, K(S). The equation was used 
with the assumption that the substrate, due to low substrate concentrations used in 
experiments, binds only to the catalytic site, while the inhibitor can bind to both sites, 
catalytic and peripheral site [30].  
The determination of kinetic constants was carried out using the GraphPad Prism 6.0 software 
(GraphPad Software, San Diego, USA). 
 
2.5. pKa determination 
The pKa values were obtained adhering to density functional theory (DFT) based 
linear regression approach [31-35]. The pKa values are computed by:  
pKa = m∆G + C          (2) 
where ∆G is a difference in Gibbs free energy between a deprotonated amine and its 
conjugated acid in aqueous solution at 298.15 K. The linear regression parameters m and C 
are found by a linear fit of pKa
exp values for a training set of compounds and their calculated 
∆G. The ∆G were calculated at LC-wPBE/6-31G+(d) level of theory with the continuum 















and water as a solvent. Thermal corrections to the free energy were computed using the ideal 
gas molecular partition functions in conjunction with the quasi-harmonic entropy correction 
as proposed by Grimme [38] with the GoodVibes program v2.0.1 [39]. A conformational 
search was done for each molecule, and the conformers with the lowest free energy were 
selected for pKa estimation. Initial conformations were generated using Open Babel’s Confab 
algorithm [40]. For symmetric diamines the statistical correction of 2.303RTln(2), where R is 
the gas constant and T is the temperature, was added to the calculated ∆G for the estimation 
of the first pKa and subtracted from the calculated ∆G for the estimation of the second pKa 
[41, 42]. At 298.15 K this correction equals 1.1795 kJ/mol. Finally, the calculated ∆G values 
of investigated 4-aminoquinolines were used for the estimation of their pKa values applying 
the equation 2. Details of applied methods, structure of amines used for preparing of test and 
control set of compounds and graphics are given in the Supplementary Material. 
 
2.6. Molecular modelling 
The crystal structure of human BChE and human AChE deposited in Protein Data Bank, PDB 
code 2PM8 [43] and 4PQE [44], respectively, were usd. The CDOCKER protocol based on 
the CHARMm force field (Accelrys Discovery Studio 2017R2 software, San Diego, USA) 
was used for docking as described previously [45]. 
 
2.7. In silico prediction of blood-brain barrier (BBB) penetration 
The BBB permeability potential was evaluated by molecu ar descriptors: the calculated 
logarithm of the octanol/water partition coefficient (logP), the molecular weight (MW), the 
polar surface area (PSA), the number of hydrogen bod donors (HBD), the number of 
hydrogen bond acceptors (HBA) and the number of rotable bonds (RB), which were 
determined in silico using the Chemicalize 2018 platform [46]. The obtained results were 
compared to the recommendations of physicochemical properties for successful central 
nervous system drugs [47]. 
 
3. Results and discussion 
Eight derivatives of quinoline were synthesized following procedures described 
previously [27, 28] with moderate to good yields. Compounds differ in the substituent 















The pKa values of 4-aminoquinolines were evaluated in silico to estimate their 
acid/base character (Table 1). The reliability of the applied method for pKa calculation was 
confirmed with low Mean absolute error (MAE) 0.20 pKa units and Maximum absolute error 
(Max AE) 0.51 pKa units, and both were far lower than the values currently targeted in the 
calculation of pKa [31, 32]. According to determined pKa values, at physiological pH, the 
terminal amino-group on C(4)-N substituent in all tested compounds (pKa2 calc.) was 
protonated. The pKa value of the aromatic nitrogen from quinoline ring (pKa1 calc.) was within 
7.05 - 8.37 and both the protonated and the non-protonated form co-existed simultaneously. 
However, at physiological pH, the majority of the tested compounds existed dominantly, 
within 76-90%, in a form where the nitrogen in the quinoline ring was protonated (double 
protonated form), while for compounds CQ2 and TFCQ2 the nitrogen was dominantly 






















CQ 8.33a - 
CQ2 7.19 9.11 
TFQ2 7.05 8.81 
CQ8 8.37 10.31 
TFQ8 7.90 10.41 
CQAd 7.96 10.53 
chloroquine 8.08b 10.77b 
CQEtOH 8.16 - 
a ref. [48] 
b ref. [49] 
 
All of the tested 4-aminoquinolines reversibly inhibited the activity of both, AChE and 
BChE, forming noncovalent interactions within the active site of the enzymes. As a measure 
of their inhibition potency, we determined the dissociation constants (± standard errors) of the 
enzyme-inhibitor complex (Ki; Table 2).  
The AChE activity was inhibited with Ki constants ranging from 0.46-11 µM (Table 
2). AChE displayed the highest affinity toward compounds with n-octylamino (TFQ8 and 
CQ8) and adamantyl group (CQAd) substituted the C(4)-amino group, demonstrating that
high lipophilic substituent, represented with long alkyl chain or adamantyl-group on C(4)-
amino group, is important for achieving high inhibition potency. Our observation is supported 
by the fact that AChE displayed the lowest affinity toward CQ having no substituent on the 
C(4)-amino group, and which has a 2.7, 14 and 18 times lower inhibition potency in 
comparison to CQ2, CQAd and CQ8, respectively. Introduction of a hydroxyethyl group on 
C(4)-amino group, as it is in CQEtOH, gave an indication about the importance of the 
presence of a basic amino group for achieving a higher inhibition potency. The replacement of 
a terminal amino group in CQ2 with hydroxyl, as it is in CQEtOH, caused about a twofold 
decrease of inhibition potency compared to CQ2. Interestingly, the 2.5-fold increase in 
inhibition of AChE, in comparison to CQ, was achieved with chloroquine although the size 
and the lipophilicity of substituent in chloroquine were comparable with that of TFQ8, CQ8 
and CQAd. It seems that the branching of the substituent on the C(4)-amino group (the 















inhibition potency toward AChE. The replacement of chlorine with stronger electron-
withdrawing trifluoromethyl group on C(7) did not affect the inhibition potency of the tested 
4-aminoquinolines indicating a minor role of C(7) sub tituent on AChE inhibition. That is 
illustrated with almost identical Ki values for corresponding pairs of substituents, i.e. CQ2 vs. 
TFQ2, and C8 vs. TFQ8. The connection of the size of the C(4)-amino group and the 
inhibition potency toward AChE was previously shown for antimalarials chloroquine, 
amopyroquine and amodiaquine. Amodiaquine and amopyroquine, with a phenyl substituent 
on the C(4)-amino group, were more potent inhibitors f electric eel AChE than chloroquine 
with an aliphatic substituent [10]. The Ki for chloroquine (Table 2) corresponds to a 
previously reported value for human erythrocyte AChE as well to that for electric eel AChE 
[10, 11].  
We evaluated the type of inhibition, whether is competitive, non-competitive or mixed, from 
the slope at the inhibition plots and dissociation c stants of the enzyme-substrate complex 
(Ks; Table 2). For majority of tested compounds, the slope was higher than zero (i.e. Ki,app 
proportionally depended on substrate concentration) and the Ks values corresponded to 
previously determined Michaelis-Menten constant (KM) [30] implying a competitive 
inhibition and binding of the tested compounds to the catalytic site of AChE. For two 
compounds with a trifluoromethyl group (TFQ2 and TFQ8), and CQ8 the slope was close to 
zero indicating no binding competition with the subtrate in the catalytic site, and a non-
competitive type of inhibition (i.e. binding of those compounds in PAS). In the case of CQAd 
we observed a deviation from linearity suggesting a mixed type of inhibition due to its 
binding to both catalytic site and PAS of AChE.   
To evaluate binding interactions we performed docking simulations with mono and double 
protonated form of amine group from a quinoline ring because no correlation between pKa 
values (Table 1) and inhibition potency (Table 2) was observed. Indeed, docking results 
confirmed these results and showed that the double protonated and mono protonated form of 
the compounds had a very similar orientation of ligands within the active site with 
CDOCKER energies for double protonated forms about 10 kcal/mol lower than the 

















Table 2. Reversible inhibition of recombinant human AChE and human BChE by 4-aminoquinolines. The enzyme-inhibtor complex 
dissociation constant (Ki ± SE) was determined by linear regression from Ki,app constants obtained from at least three experiments at 25
oC. c, n 





[I], (µM) Ki, (µM) Ks, (mM) [I], (µM) Ki, (µM) Ks, (mM) 
CQ 2-40 11±0.3 (c) 0.48±0.03 20-60 31±7 (c) 0.15±0.04 2.8 
CQ2 2-10 4.1±0.2 (c) 0.78±0.14 10-40 12± 1 (c) 0.53±0.08 2.9 
CQ8 0.25-10 0.61±0.03 (n) - 2-20 6.1±0.9 (c) 0.26±0.04 10 
TFQ2 2-10 3.6±0.2 (n) - 2-10 2.5±0.3 (c) 0.61±0.15 0.69 
TFQ8 0.25-2 0.46±0.01 (n) - 1-20 1.9±0.3 (c) 0.24±0.05 4.1 
CQAd 0.50-1.5 0.77±0.09 (m) 0.45±0.10 2-8 3.2±0.4 (m) 3.1±0.4 4.2 
CQEtOH 5-50 10±1 (c) 0.95±0.19 40-200 51±8 (c) 0.21±0.04 5.1 
















Key interactions between residues in the active sit of both cholinesterases and the tested 4-
aminoquinilines are listed in Table 3. Molecular docking showed that Trp86 in AChE, and the 
corresponding Trp82 in BChE, were the key residues for stabilisation of 4-aminoquinoline 
moiety in the choline binding site, as shown previously for tacrine and huprine, potent 
cholinesterase inhibitors [4, 50, 51]. The orientation of the quinoline group within the AChE 
active site was governed, along with Trp86, by forming interactions with Tyr337 and/or 
Tyr341 from the choline binding site. Also, all of the tested ligands (except CQ) were 
stabilized via H-bonding and/or π-interactions with Tyr72, Tyr124 or Trp286 from the 
peripheral anionic site (Table 3, Fig. 2). It is worthy of noting that molecular docking 
confirmed the evaluation of dissociation constants (cf. Table 2), and interactions of non-
competitive (TFQ2, TFQ, and CQ8), and mixed type (CQAd) inhibitors with residues from 
PAS. However, the determined inhibition potency of the tested 4-aminoquinolines can be 
attributed to additional stabilisation of substituents on the C(4)-amino group with residues in 
the AChE active site. For example, substituents on the C(4)-amino group of CQAd and 
chloroquine formed a salt bridge with Asp74, a residue in PAS involved in substrate 
















Table 3. Key interactions in the human AChE (HuAChE, accession no. P22303) and human 
BChE (HuBChE, accession no. P06267) active site gorge evaluated by molecular docking. 




























(Amide-π stacked),  
Pro285, Leu286 
(Halogen acceptor) 






























































































































Fig. 2. Orientation of ligands in the active site of AChE. Position of ligand CQAd (A) and 
ligand TFQ8 (B). Interactions are presented in green (H-bonds), orange (cation-π interaction), 
and purple (hydrophobic interactions). 
 
The most potent inhibitors of BChE were compounds with the most voluminous 
substituent on the C(4)-amino group (CQAd) or with an electron-withdrawing group on C(7) 
(TFQ2 and TFQ8). In other words, the substitution of the trifluoromethyl group in TFQ8 and 
TFQ2 by chlorine, as in CQ8 and CQ2, respectively, caused a 5 or 2-fold, decrease of their
inhibition potency. On the other hand, substitution f adamantly group in CQAd with 
diethylamino group, as in chloroquine, caused a 2-fold decrease in the inhibition potency. 
Further reduction of the size of substituent on C(4)-amine group in compounds CQ and 
CQEtOH led to an additional 10 times decrease of BChE affinity. Additionally, the Ks values 
for all compounds (Table 2) corresponded to BChE’s previously determined Michaelis-
Menten constant (KM) [30], suggesting a competitive binding of the tested compounds to the 
catalytic site of BChE. A mixed type inhibition was determined only for CQAd. Again, 
similarly to AChE, no correlation between the acid/base character of 4-aminoquinolines and 
their inhibition potency towards BChE was observed. 
Molecular modelling of the tested compounds in BChE revealed a general involvement of 
Trp82 from the choline binding site in ligand stabilisation together with Trp231 from the acyl 
pocket, amide group of Gly116 and Gly117 from the oxyanion hole, His438 from the catalytic 
triad, and Thr120 via π-stacking and H-bonding (Table 3). Interactions with Pro285 and 















interaction with Trp231 seems important for the 4-fold increased affinity of CQ2 compared to 
CQEtOH, compounds that have the amino group versus hydroxyl group on the C(4)-amino 
substituent, respectively (Fig. 3). Similarly, Košak et al. demonstrated that the same 
replacement of a hydroxyl group by an amino group in ligands increased BChE affinity up to 
picomolar range due to the interaction of an amino gr up with Trp231 [53]. Moreover, 
interactions with Trp231 and Trp82 have been proven to be decisive for ethopropazine 
selectivity toward BChE [54], and for potent dual binding inhibitors [55]. It seems that 
Trp231 has a similar role in ligand stabilisation as Trp286 from PAS in AChE [53]. 
 
 
Fig. 3. Position of ligand CQEtOH (A) and ligand CQ2 (B) in the active site of BChE. 
Interactions are presented in green (H-bonds), orange (cation-π interaction) and purple 
(hydrophobic interactions). 
 
The inhibition selectivity of the compounds was defin d with the ratio of Ki constants 
of AChE and BChE (Table 2). Overall, all of the compounds had a 1.8 to 10 times higher 
preference for AChE over BChE, except TFQ2, the compound with a trifluoromethyl group 
on C(7) and an ethylamino substituent on the C(4)-amino group, which exhibited a 1.4 times 
higher preference for BChE. The highest selectivity was displayed by CQ8, a compound with 
an n-octylamino substituent on the C(4)-amino group and chlorine on the C(7). The 
determined selectivity was comparable to that of galant mine which had about a 9 times 















Molecular modelling of the most selective inhibitor, CQ8, showed that the largest difference 
in its accommodation in the active site of AChE and BChE was the positioning of quinoline 
moiety (Fig 4). In AChE, it was stabilised with residues Tyr124, Trp286, and Tyr341, while 
in BChE with aromatic residues of Trp82, Phe329 and Trp430. Moreover, CQ8 in AChE was 
in extended form, and the protonated amino group was st bilised with Trp86 and Glu202 (Fig 
4A). Larger BChE active site allows bent conformation of CQ8 and the protonated amino 




Fig. 4. Comparison of ligand CQ8 orientations in the active site of cholinesterases. Position 
of ligand in AChE (A) and in BChE (B). Interactions are presented in green (H-bonds), 
orange (cation-π interaction) and purple (hydrophobic interactions).  
 
 Since blood brain barrier (BBB) penetration is a key request for the selection of 
compounds for further refinement of potentially centrally active drugs, we estimated the in 
silico ability of the tested compounds to cross the BBB. Figure 5 shows the radar plot of six 
physicochemical properties of the tested 4-aminoquinolines in relation to recommended 
values of CNS-active drugs, which generally have lower molecular weight (MW<450), have 
moderate hydrophobicity (logP<5), have fewer hydrogen bonds donors and acceptors (HBD< 
3 and HBA<7), fewer rotatable bonds (RB<8) and are less polar (polar surface area PSA<70 
Å2) than drugs that are not active in CNS [47]. All of the tested 4-aminoquinolines had 















surface area (up to 50.94 Å2), and optimal numbers of H-bond donors (max 2) and H-bond 
acceptors (max 3). Molecular flexibility, as characterized by the number of rotatable bonds (0 
− 10), was favourable in five out of eight compounds. Moreover, the pKa value of the most 
basic group (amine on C(4)-amino substituent) was also considered as a molecular descriptor 
whose value for CNS drugs is limited to 7.5 – 10.5 [47]. Accordingly the pKa calc. values cf. 
(Table 1) are within or close to recommended range (8.08 − 10.5). Nevertheless, the above 
results suggest that all of the tested 4-aminoquinilines have potential to penetrate the BBB and 
present a solid starting point for further structural refinement in terms of developing CNS-
active drugs.  
 
 
Fig. 5. Radar plot of physicochemical properties (molecular weight, MW; lipophilicity 
coefficient, logP; number of hydrogen bonds donors, HBD, and acceptors HBA; rotatable 
bonds, RB; polar surface area, PSA) of the tested 4-aminoquinolines. Recommended values 
for the CNS-active drugs are presented by a red line [47]. 
 
4. Conclusions 
Out of eight tested derivatives of 4-aminoquinoline that differ in C(4) and/or C(7) 
substituents, the most potent inhibitors of AChE, in lower micromolar range, were compounds 
with an n-aminooctyl chain (CQ8) or adamantyl group (CQAd), regardless of the substituent 
in position C(7). For BChE, the most potent inhibitors were CQ8 and derivatives with 















the most potent inhibitors of both AChE and BChE, as well as the most selective AChE 
inhibitor, CQ8, was positioned in AChE in extended form, while in BChE it was in a bent 
conformation. The studied derivatives of 4-aminoquinolies provided a solid starting core for 
further design of novel cholinesterase inhibitors, either as peripherally active drugs for 
treatment of Myasthenia gravis, or as centrally active drugs for use in treatment of 
neurodegenerative diseases like AD. Also, an additional advantage of such compounds is their 
simple structure and low logP which allows further st uctural refinement in terms of 
drugability.  
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Fig. 1. Chemical structure of the tested compounds. 
Fig. 2. Orientation of ligands in the active site of AChE. Position of ligand CQAd (A) and 
ligand TFQ8 (B). Interactions are presented in green (H-bonds), orange (cation-π interaction), 
and purple (hydrophobic interactions). 
Fig. 3. Position of ligand CQEtOH (A) and ligand CQ2 (B) in the active site of BChE. 
Interactions are presented in green (H-bonds), orange (cation-π interaction), and purple 
(hydrophobic interactions). 
Fig. 4. Comparison of ligand CQ8 orientations in the active site of cholinesterases. Position 
of ligand in AChE (A) and in BChE (B). Interactions are presented in green (H-bonds), 
orange (cation-π interaction) and purple (hydrophobic interactions). 
 


















• three derivatives were nanomolar selective AChE inhib tors 
• the quinoline group is primarily stabilised by the choline binding site residues 
• 4-aminoquinoline derivatives exhibit slight selectivity toward AChE over BChE 
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